Ovation Science and Skinvisible Strengthen Partnership in Obesity Market with New Cannabinoid Delivery Patents
Ovation Science and Skinvisible Pharmaceuticals have expanded their partnership to advance patent-pending Invisicare® cannabinoid delivery technology for obesity and metabolic health. The collaboration leverages THC-V research, new patent protection, and the growing US$150B obesity therapy market.
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Skinvisible Pharmaceuticals announces major progress in 2024-2025 through its licensee, Quoin Pharmaceuticals, in developing QRX003 for Netherton Syndrome using Invisicare technology. With FDA clearance, global clinical trials, and regulatory success, Skinvisible advances innovative topical and transdermal therapies.
Skinvisible Announces Significant Progress in Licensee’s Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV – February 14, 2024 – Skinvisible, Inc. (“Skinvisible”) (OTCQB: SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. (“Quoin”) (NASDAQ: QNRX). The trials focus on the innovative formulation “QRX003,” powered by Skinvisible’s Invisicare® proprietary drug delivery technology, to address the challenges […]






